Estrella Immunopharma, Inc. (ESLAW) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
5858 HORTON STREET, SUITE 370 EMERYVILLE, CA 94608 |
| State of Incorp. | |
| Fiscal Year End | June 30 |
| Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 9/30/2024 MRQ | 6/30/2024 | 12/31/2022 | 12/31/2021 | |||
|---|---|---|---|---|---|---|
| ASSETS | ||||||
| Current Assets | ||||||
| Cash, cash equivalents, and short-term investments | 4,165 | 41 | 479 | |||
| Cash and cash equivalent | 4,165 | 41 | 479 | |||
| Prepaid expense | 12 | 137 | ||||
| Other undisclosed current assets | 289 | |||||
| Total current assets: | 4,454 | 52 | 616 | |||
| Noncurrent Assets | ||||||
| Asset, held-in-trust | 9,671 | 45,187 | ||||
| Other undisclosed noncurrent assets | ||||||
| Total noncurrent assets: | 9,671 | 45,187 | ||||
| TOTAL ASSETS: | 4,454 | 9,724 | 45,803 | |||
| LIABILITIES AND EQUITY | ||||||
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts payable and accrued liabilities, including: | 173 | 329 | 3 | |||
| Accrued liabilities | 173 | 51 | ||||
| Other undisclosed accounts payable and accrued liabilities | 278 | 3 | ||||
| Due to related parties | ✕ | ✕ | 50 | |||
| Other undisclosed current liabilities | 8 | 694 | 70 | |||
| Total current liabilities: | 181 | 1,073 | 73 | |||
| Noncurrent Liabilities | ||||||
| Liabilities, other than long-term debt | 29 | |||||
| Deferred income tax liabilities | 29 | |||||
| Other undisclosed noncurrent liabilities | 1,551 | 1,551 | ||||
| Total noncurrent liabilities: | 1,580 | 1,551 | ||||
| Total liabilities: | 181 | 2,653 | 1,624 | |||
| Temporary equity, including noncontrolling interest | 9,326 | 45,186 | ||||
| Equity | ||||||
| Equity, attributable to parent | 4,273 | (2,256) | (1,006) | |||
| Common stock | 4 | 0 | 0 | |||
| Treasury stock, value | (354) | |||||
| Additional paid in capital | 24,125 | |||||
| Accumulated deficit | (19,500) | (2,256) | (1,006) | |||
| Total equity: | 4,273 | (2,256) | (1,006) | |||
| TOTAL LIABILITIES AND EQUITY: | 4,454 | 9,724 | 45,803 | |||
Income Statement (P&L) ($ in thousands)
| 9/30/2024 TTM | 6/30/2024 | 12/31/2022 | 12/31/2021 | ||
|---|---|---|---|---|---|
| Revenues | 3,759 | ||||
| Net investment income | 3,759 | ||||
| Gross profit: | 3,759 | ||||
| Operating expenses | (7,310) | (1,368) | (179) | ||
| Other undisclosed operating loss | (3,759) | (201) | (70) | ||
| Operating loss: | (7,310) | (1,570) | (249) | ||
| Nonoperating income (Investment Income, Nonoperating) | 654 | 1 | |||
| Loss from continuing operations before income taxes: | (7,310) | (915) | (248) | ||
| Income tax expense | (2) | (81) | (52) | ||
| Other undisclosed loss from continuing operations | |||||
| Loss from continuing operations: | (7,312) | (996) | (300) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | (300) | |
| Other undisclosed net income | 52 | ||||
| Net loss attributable to parent: | (7,312) | (996) | (248) | ||
| Preferred stock dividends and other adjustments | (253) | (4,635) | |||
| Net loss available to common stockholders, diluted: | (7,312) | (1,249) | (4,883) | ||
Comprehensive Income ($ in thousands)
| 9/30/2024 TTM | 6/30/2024 | 12/31/2022 | 12/31/2021 | ||
|---|---|---|---|---|---|
| Net loss: | (7,312) | (996) | (248) | ||
| Comprehensive loss, net of tax, attributable to parent: | (7,312) | (996) | (248) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.